Clinical trial
Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)
NCT06050928 is registered in ClinicalTrials.gov with Escient Pharmaceuticals, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria (CALM-CIndU)
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 30, 2023
- Completion date
- October 22, 2024
- Enrollment
- 33 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.